Kim H, Jang J, Heo YJ, et al. - Gastric cancer tissues from patients recruited in a clinical trial of pembrolizumab were evaluated, and 39 cases were investigated by the researchers to contrast the outcomes of digital image analysis and pathologists’ interpretations for prognosticating response to pembrolizumab in gastric cancer patients. A total of 33 out of 39 cases exhibited concordant outcomes in the direct comparisons of digital image analyses and pathologists’ interpretations. In 6 cases, weak staining of PD-L1, anthracotic pigment deposits, or decalcification artifacts led to discordant outcomes, and all the cases were challenging. In statistical analyses, for prognosticating responses to pembrolizumab, PD-L1 expression as interpreted by pathologists and digital image analysis did not vary significantly. In conclusion, in most cases, digital image analyses and pathologists’ interpretations demonstrated concordant outcomes for PD-L1 combined positive scores, and the prediction performances of each were not significantly distinctive.